| 1.8 0.05 (2.86%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.26  |
1-year : | 2.49 |
| Resists | First : | 1.94 |
Second : | 2.14 |
| Pivot price | 1.83  |
|||
| Supports | First : | 1.62 | Second : | 1.34 |
| MAs | MA(5) : | 1.73 |
MA(20) : | 1.88 |
| MA(100) : | 2.08 |
MA(250) : | 2.69 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 27.8 |
D(3) : | 17.9 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 6.55 | Low : | 1.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HIND ] has closed above bottom band by 41.2%. Bollinger Bands are 33% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.14 - 2.15 | 2.15 - 2.16 |
| Low: | 1.73 - 1.74 | 1.74 - 1.75 |
| Close: | 1.79 - 1.8 | 1.8 - 1.81 |
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Sat, 24 Oct 2026
Vyome Holdings, Inc. Estimates – NASDAQ:HIND - TradingView
Fri, 02 Oct 2026
Vyome Holdings, Inc. (NASDAQ: HIND) Share Price, HIND Stock News, HIND Share Price & Updates - kalkine.ca
Wed, 12 Aug 2026
Vyome Holdings, Inc Q2 2026: Revenue $26955 Net loss $(685,556), EPS $(0.10) — 10-Q Summary - TradingView
Thu, 25 Jun 2026
HIND Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 28 May 2026
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet - Business Wire
Tue, 12 May 2026
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 3.65e+006 (%) |
| Held by Institutions | 52.8 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.21e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 200 % |
| Return on Equity (ttm) | -48.8 % |
| Qtrly Rev. Growth | 129720 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 26230 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|